Public Assessment Report

UKPAR

Ibuprofen 400mg Tablets

(Ibuprofen)

UK Licence No: PL 00037/0674

Abbott Laboratories Limited.
LAY SUMMARY

Ibuprofen 400mg Tablets
(Ibuprofen)

This is a summary of the Public Assessment Report (PAR) for Ibuprofen 400mg Tablets (PL 00037/0674). It explains how Ibuprofen 400mg Tablets was assessed and its authorisation recommended, as well as its conditions of use. It is not intended to provide practical advice on how to use how Ibuprofen 400mg Tablets.

For practical information about using Ibuprofen 400mg Tablets patients should read the package leaflet or contact their doctor or pharmacist.

What are Ibuprofen 400mg Tablets and what are they used for?
This medicine is used to relieve pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis (including juvenile rheumatoid arthritis or Still's disease), arthritis of the spine, ankylosing spondylitis, swollen joints, frozen shoulder, bursitis, tendonitis, tenosynovitis, lower back pain, sprains and strains.

Ibuprofen can also be used to treat other painful conditions such as toothache, pain after operations, period pain and headache, including migraine.

This application is the same as Brufen Tablets 400 mg (PL 46302/0006) which is already authorised.

The company (Mylan Products Ltd) that makes Brufen Tablets 400 mg (PL 46302/0006) has agreed that its scientific data can be used as a basis for the grant of an identical licence for Ibuprofen 400mg Tablets.

How do Ibuprofen 400mg Tablets work?
This medicine contains the active ingredient ibuprofen which belongs to a group of medicines called NSAIDs (non-steroidal anti-inflammatory drugs). They reduce fever, relieve pain and have an anti-inflammatory effect.

How are Ibuprofen 400mg Tablets used?
The pharmaceutical form of this medicine is a film-coated tablet and the route of administration is oral (by mouth).

The patient should always use this medicine exactly as their doctor has told them. The patient should refer to the package label or carton or check with their doctor or pharmacist if they are not sure.

These tablets should be taken with or after food, with a glass of water. Ibuprofen should be swallowed whole and not chewed, broken, crushed or sucked to help prevent discomfort in the mouth or irritation in the throat.

DOSAGE:
Adults and children over 12 years:
The usual dosage is 600 to 1800mg spread throughout the day. The patient’s doctor may choose to increase this depending on what they are being treated for; but no more than 2400mg should be taken in one day.
**Children:**
The usual daily dose is 20mg per kg of bodyweight each day, given in divided doses. For young children, more suitable formulations are available. Ibuprofen should NOT be taken by children weighing less than 7kg. In cases of severe juvenile arthritis, the patient’s doctor may increase the dosage up to 40mg/kg in divided doses.

The patient should avoid excessive use of painkillers. If the patient usually takes painkillers, especially combinations of different painkillers, they may damage their kidneys, the patient should tell their doctor if they are already taking another painkiller before taking this medicine and their doctor will decide whether the patient should take this medicine. This risk may be increased if the patient is dehydrated.

This medicine can only be obtained with a prescription.

For further information on how Ibuprofen 400mg Tablets are used, refer to the package leaflet and Summary of Product Characteristics available on the Medicines and Healthcare products Regulatory Agency (MHRA) website.

**What benefits of Ibuprofen 400mg Tablets have been shown in studies?**
Ibuprofen 400mg Tablets is considered identical to previously authorised Brufen Tablets 400 mg (PL 46302/0006) with the same benefits and risks. So, no new studies have been provided for Ibuprofen 400mg Tablets, but reference is made to the studies for Brufen Tablets 400 mg (PL 46302/0006).

**What are the possible side effects from Ibuprofen 400mg Tablets?**
Like all medicines, this medicine can cause side effects, although not everybody gets them.

Ibuprofen 400mg Tablets is considered to be identical to the previously authorised application for Brufen Tablets 400 mg (PL 46302/0006) with the same benefits and risks.

For a full list of all the side effects reported with Ibuprofen 400mg Tablets see section 4 of the package leaflet, available on the Medicines and Healthcare products Regulatory Agency (MHRA) website.

For the full list of restrictions, see the package leaflet.

**Why was Ibuprofen 400mg Tablets Approved?**
The MHRA decided that the benefits of Ibuprofen 400mg Tablets are greater than the risks and recommended that they are approved for use.

**What measures are being taken to ensure the safe and effective use of Ibuprofen 400mg Tablets?**
A Risk Management Plan has been developed to ensure that Ibuprofen 400mg Tablets are used as safely as possible. Based on this plan, safety information has been included in the Summary of Product Characteristics and the package leaflet for Ibuprofen 400mg Tablets including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore, new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously.

**Other information about Ibuprofen 400mg Tablets**
A Marketing Authorisation were granted in the UK on 02 March 2018.

The full PAR for Ibuprofen 400mg Tablets follows this summary.
For more information about treatment with Ibuprofen 400mg Tablets read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in April 2018.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>I</th>
<th>Introduction</th>
<th>Page 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>II</td>
<td>Quality aspects</td>
<td>Page 7</td>
</tr>
<tr>
<td>III</td>
<td>Non-clinical aspects</td>
<td>Page 9</td>
</tr>
<tr>
<td>IV</td>
<td>Clinical aspects</td>
<td>Page 9</td>
</tr>
<tr>
<td>V</td>
<td>User consultation</td>
<td>Page 9</td>
</tr>
<tr>
<td>VI</td>
<td>Overall conclusion, benefit/risk assessment and recommendation</td>
<td>Page 9</td>
</tr>
<tr>
<td></td>
<td>Table of content of the PAR update</td>
<td>Page 12</td>
</tr>
</tbody>
</table>
I  INTRODUCTION

The Medicines and Healthcare products Regulatory Agency (MHRA) granted Abbott Laboratories Limited a Marketing Authorisation for the medicinal product Ibuprofen 400mg Tablets (PL 00037/0674) on 02 March 2018.

This product is a prescription only medicine (POM) and is indicated:

- for its analgesic and anti-inflammatory effects in the treatment of rheumatoid arthritis (including juvenile rheumatoid arthritis or Still's disease), ankylosing spondylitis, osteoarthritis and other non-rheumatoid (seronegative) arthropathies.
- in the treatment of non-articular rheumatic conditions, Ibuprofen is indicated in periarticular conditions such as frozen shoulder (capsulitis), bursitis, tendonitis, tenosynovitis and low back pain; Ibuprofen can also be used in soft tissue injuries such as sprains and strains.
- for its analgesic effect in the relief of mild to moderate pain such as dysmenorrhoea, dental and post-operative pain and for symptomatic relief of headache, including migraine headache.

This application was submitted as a simple abridged (informed consent) application according to Article 10c of Directive 2001/83/EC, as amended.

The application cross-refers to the medicinal product Brufen Tablets 400 mg which was first authorised to the marketing authorisation holder (MAH) Knoll Pharma Limited (PL 13530/0006) on 01 April 1993 and subsequently underwent several changes of ownership procedures of which the most recent was to the current MAH Mylan Products Limited (PL 46302/0006) on 15 August 2016.

Ibuprofen is a propionic acid derivative with analgesic, anti-inflammatory and antipyretic activity. The drug's therapeutic effects as an NSAID is thought to result from its inhibitory effect on the enzyme cyclo-oxygenase, which results in a marked reduction in prostaglandin synthesis.

No new data were submitted nor were necessary to be submitted for this application, as the data are identical to the data for the previously granted cross-referenced product.

The MHRA has been assured that acceptable standards of Good Manufacturing Practice (GMP) are in place for this product type at all sites responsible for the manufacture and assembly of this product.
II QUALITY ASPECTS

II.1 Introduction
This is an abridged application for Ibuprofen 400mg Tablets (PL 00037/0674) submitted under Article 10c of Directive 2001/83/EC, as amended.

The application cross-refers to the medicinal product Brufen Tablets 400 mg which was first authorised to the marketing authorisation holder (MAH) Knoll Pharma Limited (PL 13530/0006) on 01 April 1993 and subsequently underwent several changes of ownership procedures of which the most recent was to the current MAH Mylan Products Limited (PL 46302/0006) on 15 August 2016. The application is considered valid.

II.2. Drug Substance
Drug substance specification
The proposed drug substance specification is consistent with the details registered for the cross-reference product.

II.3. Medicinal Product
Name
The proposed product name for this application is Ibuprofen 400mg Tablets. The product has been named in line with current requirements.

Strength, pharmaceutical form, route of administration, container and pack sizes
Each film-coated tablet contains 400mg ibuprofen. The finished product is packaged into:

- Blister packs comprising of transparent polyvinyl chloride (PVC) with aluminium foil backing in pack sizes 60 or 100 tablets.

or

- Blister packs comprising of transparent polyvinyl chloride (PVC) film coated on one face with polyvinylidene chloride (PVDC) with aluminium foil backing in pack sizes 60 or 100 tablets. Not all pack sizes may be marketed.

The proposed shelf life of the unopened product (both blister pack types) is 36 months with the storage conditions ‘Do not store above 25°C, store in the original package.’

The proposed packaging, shelf-life and storage conditions are consistent with the details registered for the cross-reference product.

Legal status
Prescription only medicine (POM).

Marketing Authorisation Holder/Contact Persons/Company
Abbott Laboratories Limited, Abbott House, Vanwall Business Park, Vanwall Road, Maidenhead, Berkshire, SL6 4XE, UK.

The Qualified Person (QP) responsible for pharmacovigilance is stated and a satisfactory CV has been provided.
Manufacturers
The proposed manufacturing sites are consistent with those registered for the cross-reference product and evidence of Good Manufacturing Practice (GMP) compliance has been provided.

Qualitative and quantitative composition
The proposed composition is consistent with the details registered for the cross-reference product.

Manufacturing process
The proposed manufacturing processes are consistent with the details registered for the cross-reference product and the maximum batch size is stated.

Finished product/shelf-life specification
The proposed finished product specification is in line with the details registered for the cross-reference products.

TSE Compliance
None of the excipients used contain material of animal or human origin. This is consistent with the reference product.

Bioequivalence
No bioequivalence data are required to support this simple abridged application because the proposed product is manufactured to the same formula utilising the same processes as the cross-reference product, Brufen Tablets 400 mg (PL 46302/0006).

Expert Report
The applicant cross-refers to the data for Brufen Tablets 400 mg (PL 46302/0006) to which this application is claimed to be identical. This is acceptable.

Product Name and Appearance
See Section II.3 ‘Medicinal Product; Name’ for details of the proposed product name. The appearance of the product is identical to that of the cross-reference product.

II.4 Discussion on chemical, pharmaceutical and biological aspects
The data submitted with this application is acceptable. The grant of a Marketing Authorisation is recommended.
III NON-CLINICAL ASPECTS

Introduction
As this is an abridged application submitted under Article 10c of Directive 2001/83/EC, as amended, no new non-clinical data have been supplied and none are required.

Ecotoxicity/environmental risk assessment (ERA)
Suitable justification has been provided for non-submission of an Environmental Risk Assessment. As the application is an identical version of an already authorised product, it is not expected that environmental exposure will increase following approval of the Marketing Authorisation for the proposed product.

Discussion on the non-clinical aspects
The grant of a Marketing Authorisation is recommended.

IV CLINICAL ASPECTS

Introduction
As this is an abridged application submitted under Article 10c of Directive 2001/83/EC, as amended, no new clinical data have been supplied and none are required.

Risk Management Plan (RMP)
The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended.

There are no differences from the reference product in terms of proposed uses, maximum pack size / strength or pharmaceutical form / formulation that would have any implications for safety.

In line with the reference product, the applicant proposes only routine pharmacovigilance and routine risk minimisation measures for all safety concerns (labelling in the SmPC and the PIL). This is agreed and the RMP is approved.

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation.

The MAH is reminded that an updated RMP should be submitted, whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile.

Discussion on the clinical aspects
The grant of a Marketing Authorisation is recommended.

V User consultation
A user consultation with target patient groups on the package information leaflet (PIL) has been performed on the basis of a bridging report making reference to the PIL for Brufen 200mg, 400 mg and 600 mg tabletter (Abbott Scandinavia AB). The bridging report submitted by the applicant is acceptable.

VI Overall conclusion, benefit/risk assessment and recommendation
The quality of the product is acceptable, and no new non-clinical or clinical safety concerns have been identified. The applicant’s product is identical to the cross-reference product. Extensive clinical experience with ibuprofen is considered to have demonstrated the therapeutic value of the compound. The benefit/risk balance is, therefore, considered to be positive.
Summaries of Product Characteristics (SmPC), Patient Information Leaflets (PIL) and Labels

The SmPC and PIL are consistent with the details registered for the cross-reference products.

In accordance with Directive 2010/84/EU the Summaries of Product Characteristics (SmPCs) and Patient Information Leaflets (PILs) for products granted Marketing Authorisations at a national level are available on the MHRA website.

The approved labelling for this medicine is presented below:
Annex 1

Table of content of the PAR update

Steps taken after the initial procedure with an influence on the Public Assessment Report (Type II variations, PSURs, commitments)

<table>
<thead>
<tr>
<th>Scope</th>
<th>Procedure number</th>
<th>Product information affected</th>
<th>Date of start of the procedure</th>
<th>Date of end of procedure</th>
<th>Approval/ non approval</th>
<th>Assessment report attached Y/N (version)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>